|
Post by lakers on Oct 27, 2015 1:08:47 GMT -5
Title: USE OF ULTRARAPID ACTING INSULIN Document Type and Number: WIPO Patent Application WO/2015/148905 Kind Code: A1 Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. Inventors: BOSS, Anders, Hasager (285 Cold Soil Road, Princeton, NJ, 08540, US) PETRUCCI, Richard (917 Silvermine Road, New Canaan, CT, 06840, US) Application Number: US2015/022956 Publication Date: 10/01/2015 Filing Date: 03/27/2015 View Patent Images: Download PDF WO/2015/148905A1 www.freepatentsonline.com/WO2015148905A1.html
|
|
|
Post by careful2invest on Oct 27, 2015 5:53:07 GMT -5
Lakers, Does your post indicate that SNY can now promote AFREZZA with Ultra Rapid Acting Insulin on the label and in their advertisements in the US?
I am also wondering if SNY can use this "Ultra Rapid Acting Insulin" claim in Israel upon launch in that country?
I tried to post this question on Yahoo mb, but it keeps getting deleted.
Thank you in advance.
GLTA TRUE LONGS!
|
|
|
Post by cathode on Oct 27, 2015 11:17:09 GMT -5
|
|